This content is from the original 2022 HFSA AHFTC Board Certification Review OnDemand Content

2023 BCR Spotlight: Cardiac Transplantation will focus on the latest advances in the field of cardiac transplantation, utilizing presentations from the 2022 HFSA AHFTC Board Review course. This seminar will focus on the key aspects of cardiac transplantation, with a particular emphasis on three primary learning objectives. Firstly, the seminar will help attendees to identify the optimal time for and appropriate candidates for evaluation for advanced therapies such as heart transplant. Secondly, it will cover the current guidelines for managing immunosuppression in heart transplant patients. Lastly, attendees will learn how to diagnose transplant complications early and manage them most effectively. By the end of the seminar, attendees will be equipped with the tools and knowledge needed to provide the best possible care to their patients.

This program is intended for physicians, nurses, nurse practitioners, physician assistants, and advanced practice professionals that provide care to patients with heart failure.

Program Co-Chairs
Akshay S. Desai, MD, MPH, FHFSA - Brigham and Women’s Hospital, Boston, MA
Maria Rosa Costanzo, MD - Advocate Heart Institute, Naperville, IL
Nancy Sweitzer, MD, PhD, FHFSA - Washington University School of Medicine, St. Louis, MO
Jonathan Rich, MD, FHFSA - Northwestern University Feinberg School of Medicine, Chicago, IL


Speakers
Michelle Kittleson, MD, PhD - Cedars Sinai Medical Center, Los Angeles, CA
Sean Pinney, MD - University of Chicago, Chicago, IL
Nancy Sweitzer, MD, PhD, FHFSA - Washington University School of Medicine, St. Louis, MO

Advanced Heart Failure: Defining the Phenotype and Patient Selection for Advanced Therapies – N. Sweitzer
Immunology: The Basics, PRA, Sensitization, Crossmatch – S. Pinney
Rejection: Cellular and Antibody Mediated - S. Pinney
Managing Immunosuppression and Drugs – M. Kittleson
Heart Transplant, Clinical Outcomes and Complications – M. Kittleson

In support of improving patient care, The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Heart Failure Society of America designates this educational activity for a maximum of 2.50 AMA PRA Category 1 Credits™.  
 
The Heart Failure Society of America designates this live activity for a maximum of 2.50 AMA PRA Category 1 Credits™.  Successful completion of this CME activity, which includes participation in the evaluation component and post-test with 75% passing score, enables the participant to earn up to 2.50 MOC points in the Maintenance of Certification (MOC) program.

The Heart Failure Society of America (HFSA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its educational activities. HFSA has a disclosure policy that requires oral presenters to disclose all relevant financial relationships for themselves and their spouse or partner during the past 24 months with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients and related to the content of the activity, whether or not these commercial entities are supporters of the activity.

Speakers will have a disclosure slide at the beginning of each presentation. All potential conflicts of interests have been resolved in accordance with the ACCME Updated Standards for Commercial Support.

The following faculty and/or accreditors with ability to control content for this activity have no conflict of interest:

• Michelle Kittleson, MD, PHD
• Jonathan Rich, MD, FHFSA
• Nancy Sweitzer, MD, PhD, FHFSA

The following faculty and/or accreditors with ability to control content for this activity have listed the below disclosures:

• Maria Rosa Costanzo, MD, FHFSA – Consultant: Nuwellis; Board Member: Nuwellis; Advisory Panel: Boehringer Ingeheim; Research Support: Abbott Laboratories, Novartis, V-Wave
• Akshay S. Desai, MD, MPH, FHFSA – Consultant: Abbott Laboratories, AstraZeneca, BayerAG, Novartis, Cytokinetics, DalCor Pharmaceuticals, GloaxoSmithKline, Merck, Relyspa, Regenron Pharmaceuticals, Verily, Biofourmis, Sun Pharmaceuticals, Lupin Pharmaceuticals, Avidity; Research Support: Abbott Laboratories, AstraZeneca, Bayer AG, Novartis, Alnylam Pharmaceuticals
• Sean Pinney, MD – Consultant: Abbott Laboratories, CareDX, Medtronic, Procyrion, TransMedics

Off-Label Disclosure
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.